A Pre-Conference Program; additional registration is required.
Thursday, Nov. 11, 2021*
7:30 a.m. – 6 p.m. EST
*Dates and times subject to change.
While immunotherapy treatments, particularly anti-PD-1 therapies, have improved outcomes for some patients, the issue of post-treatment relapse remains a large problem. The proper choice of treatment after relapse on checkpoint inhibition is therefore a critical issue to solve. This symposium will explore the preclinical and clinical data on sequencing of immunotherapies, in order to improve patient outcomes and ensure the field of immunotherapy remains at the forefront of oncology care.
- Elizabeth M. Jaffee, MD – Sidney Kimmel Cancer Center, Johns Hopkins University
- Samir N. Khleif, MD – Georgetown University Medical Center
- Ira Mellman, PhD – Genentech
- Padmanee Sharma, MD, PhD – The University of Texas MD Anderson Cancer Center
The target audience for this symposium includes basic, translational, and clinical researchers from all work settings with an interest in the biological foundation of resistance to immune checkpoint inhibitors and methods to overcome this.
At the conclusion of this activity, participants should be able to:
- Describe the current understanding of resistance to and relapse on checkpoint inhibitor therapies
- Outline the biological fundamentals of immunotherapy sequencing and the effects on the immune profile and tumor microenvironment
- Summarize clinical advancements in sequencing of immune therapies for cancer
*Program schedule subject to change.